US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Monkeypox Concept

2,024.54

-7.1163-0.35%

Number of Gainers:4

Number of Losers:6

Number of Flat:1

PE:- -

High:2,052.89

Open:2,052.89

Low:2,016.27

Close:2,031.66

Volume:22.33M

Turnover:1.06B

Market Cap:224.10B

Float Cap:223.40B

Loading ...

Viatris Price Target Raised to $20.00/Share from $15.00 by Argus Research

Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026

Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating

MT Newswires Live

Tonix Pharmaceuticals Files Form 3 for Chief Commercial Officer Thomas Englese

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

THOMSON REUTERS

Virax Biolabs Enters At-the-Market Offering Agreement for Ordinary Share Sales

Quest Diagnostics CEO James E. Davis Sells 10,000 Shares Worth $2.43 Million

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Gilead’s Arcus-Backed Cancer Trial Reaches Completion, Setting Up a Key Immuno-Oncology Catalyst

Tonix Highlights Tonmya Fibromyalgia Launch, Pipeline Progress in Investor Presentation

Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028

MT Newswires Live

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

THOMSON REUTERS

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Quest Diagnostics Inc. Stock Outperforms Competitors on Strong Trading Day

Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares

Emergent BioSolutions Secures New BARDA Anthrax Contract

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Moderna Inc. Stock Advances 9.9%, Outperforms Peers

Emergent BioSolutions: Got Contract Modification of Barda Av7909 Contract from Office of Assistant Secretary for Preparedness and Response

THOMSON REUTERS

Emergent BioSolutions - Contract Modification for Procurement of Additional Cyfendus (Av7909) Doses - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK4583/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":2024.5422,"timestamp":1789156799999,"preClose":2031.6586,"halted":0,"volume":22330540,"delay":0,"changeRate":-0.003503,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-7.116333,"latestTime":"09-11 16:00:00 EDT","open":2052.8862,"high":2052.8862,"low":2016.2698,"amount":1059245261.617174,"amplitude":0.018023,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.542352,"peRate":-74.230044,"turnoverRate":0.008268,"increases":4,"decrements":6,"flats":0,"marketCap":224097157967.5,"floatMarketCap":223402998500.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":2052.8862,"amplitude":0.018023,"preClose":2031.6586,"low":2016.2698,"pbRate":"6.542352","latestPrice":2024.5422,"volume":22330540,"delay":0,"open":2052.8862,"prevYearClose":1682.3505,"prevWeekClose":2112.7637,"prevMonthClose":2060.2607,"prevQuarterClose":1802.0435,"fiveDayClose":2118.1284,"twentyDayClose":1957.7635,"sixtyDayClose":1802.5063,"secType":"PLATE","market":"US","turnoverRate":0.008268,"peRate":-74.230044,"marketCap":224097157967.5,"floatMarketCap":223402998500.5,"timestamp":1789156799999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":4,"down":6,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665373196","title":"Viatris Price Target Raised to $20.00/Share from $15.00 by Argus Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373196","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373196?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:00","pubTimestamp":1788872400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VTRS/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VTRS","BK4583","BK4588","LU2087621335.USD","LU1839511570.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665237857","title":"Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665237857","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665237857?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:31","pubTimestamp":1788870661,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals names Rob Myers chief medical officer effective Sept. 21, 2026Mirum named Rob Myers as chief medical officer, effective Sept. 21, 2026, to lead global medical and clinical develo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLbq3cV8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU0289739699.SGD","TBXU","MIRM","MEDI","IE00BKVL7J92.USD","LU1934455277.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU0859254822.USD","LU1571399168.USD","LU1674673428.USD","LU2089984988.USD","LU2468319806.SGD","LU0965509010.AUD","BK4578","LU1057294990.SGD","GILD","LU1585245621.USD","BK4550","BIB","BK4532","BMED","LU1778281490.HKD","LU1066051498.USD","LU0965508806.USD","BK4568","BK4588","LU1674673691.USD","IE00B3T34201.USD","LU0882574055.USD","LU1037948541.HKD","IBBQ","LU0965509101.SGD","BBH","SG9999015986.USD","IBB","IE0002270589.USD","LU2357627491.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","SG9999015978.USD","TMED","LU1037948897.HKD","BK4583","BK4566","LU1839511570.USD","LU1934455194.USD","BK4585","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665930320","title":"Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2665930320","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665930320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:07","pubTimestamp":1788869225,"startTime":"0","endTime":"0","summary":"Viatris (VTRS) has an average rating of hold and mean price target of $18.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU2087621335.USD","BK4583","BK4588","BK4585","LU1839511570.USD","VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322102","title":"Tonix Pharmaceuticals Files Form 3 for Chief Commercial Officer Thomas Englese","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322102","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322102?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:06","pubTimestamp":1788865578,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals files Form 3 for Chief Commercial Officer Thomas EngleseChief Commercial Officer Thomas Englese filed an initial Form 3 for Tonix, reporting 694 shares held directly.Disclosure a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL12LX2W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322514","title":"Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322514?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6LGRLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4139","TNXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665359005","title":"Virax Biolabs Enters At-the-Market Offering Agreement for Ordinary Share Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2665359005","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665359005?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:20","pubTimestamp":1788553236,"startTime":"0","endTime":"0","summary":"Virax Biolabs enters at-the-market offering agreement for ordinary share salesVirax Biolabs filed a legal opinion supporting the issuance and sale of ordinary shares.Disclosure referenced an at-the-ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDLh8z0d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4175","VRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664804986","title":"Quest Diagnostics CEO James E. Davis Sells 10,000 Shares Worth $2.43 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804986","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804986?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:06","pubTimestamp":1788469565,"startTime":"0","endTime":"0","summary":"Quest Diagnostics CEO James E. Davis sells 10,000 shares worth $2.43 millionQuest Diagnostics CEO and President James E. Davis sold 10,000 common shares on Sept. 1, 2026 at USD 242.72.Direct holdings ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLGspXp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Quest Diagnostics CEO James E. Davis Sells 10,000 Shares Worth $2.43 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DGX","BK4585","LU1854103824.USD","BK4588","LU0823417653.USD","BK4583","LU2506951875.HKD","LU1854104046.USD","LU2506952097.USD","LU2506952170.USD","LU2506951958.HKD","BK4567","LU0950375773.USD","BK4196","LU0823417737.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664012018","title":"Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2664012018","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664012018?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:35","pubTimestamp":1788467700,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily GainsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  advanced 1.08% to $151.22 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 1.06% to 7,747.71 and the Dow Jones Industrial Average  rising 1.18% to 53,686.11.Gilead Sciences Inc. closed 3.86% short of its 52-week high of $157.29, which the company reached on February 11th.The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson  rose 1.17% to $278.43, Pfizer Inc.  fell 0.72% to $28.81, and Abbott Laboratories  fell 1.52% to $108.79.Trading volume  remained 2.3 million below its 50-day average volume of 6.8 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 3, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4139","LU1839511570.USD","BK4578","LU1037948897.HKD","LU0859254822.USD","LU1057294990.SGD","LU1061106388.HKD","TBXU","IE00BKVL7J92.USD","GILD","LU0965509101.SGD","LU1066053197.SGD","IE00B7SZLL34.SGD","SG9999015952.SGD","IE00B3T34201.USD","LU0965509283.SGD","BIB","SG9999015978.USD","BBH","LU1674673428.USD","LU1430594728.SGD","LU1934455277.USD","LU2089984988.USD","SG9999015986.USD","IE00BZ1G4Q59.USD","LU1023059063.AUD","LU1674673691.USD","LU2112291526.USD","IE00BSNM7G36.USD","LU0965508806.USD","LU2324357040.USD","LU0882574055.USD","LU2357627491.SGD","BMED","LU2468319806.SGD","BK4550","LU0320765992.SGD","LU1934455863.HKD","BK4568","MEDI","LU1037948541.HKD","LU0122379950.USD","SG9999015945.SGD","BK4532","IE00B19Z3581.USD","BK4583","LU0861579265.USD","LU1585245621.USD","LU0889565916.HKD","LU2087621335.USD","BK4588","IBBQ","LU1571399168.USD","BK4585","LU0965509010.AUD","LU1066051498.USD","LU1934455194.USD","BK4566","IBB","LU0114720955.EUR","LU0234570918.USD","IE0002270589.USD","LU1778281490.HKD","TMED","LU0823416689.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664805389","title":"Gilead’s Arcus-Backed Cancer Trial Reaches Completion, Setting Up a Key Immuno-Oncology Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2664805389","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664805389?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:30","pubTimestamp":1788453034,"startTime":"0","endTime":"0","summary":"Gilead Sciences ($GILD) announced an update on their ongoing clinical study. Gilead Partner Study Marks Milestone in First-Line Stomach Cancer Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gileads-arcus-backed-cancer-trial-reaches-completion-setting-up-a-key-immuno-oncology-catalyst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gileads-arcus-backed-cancer-trial-reaches-completion-setting-up-a-key-immuno-oncology-catalyst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0289739699.SGD","IBBQ","BK4532","LU1066053197.SGD","LU1585245621.USD","IE00B19Z3581.USD","LU0965508806.USD","LU0882574055.USD","BMED","LU1057294990.SGD","LU0122379950.USD","LU0965509101.SGD","LU1674673428.USD","BBH","LU1023059063.AUD","LU2112291526.USD","IE00B19Z3B42.SGD","LU0965509283.SGD","LU2468319806.SGD","BK4139","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU2089984988.USD","LU0823416689.USD","IBB","SG9999015945.SGD","LU0861579265.USD","TMED","LU1430594728.SGD","LU1571399168.USD","LU1066051498.USD","GILD","TBXU","BK4566","BK4583","BIB","LU1934455277.USD","LU2324357040.USD","MEDI","LU1778281490.HKD","SG9999015952.SGD","LU1037948541.HKD","IE00B7SZLL34.SGD","LU0058720904.USD","LU1839511570.USD","IE00B3T34201.USD","LU1934455194.USD","SG9999015978.USD","LU1061106388.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877169","title":"Tonix Highlights Tonmya Fibromyalgia Launch, Pipeline Progress in Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877169","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877169?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:35","pubTimestamp":1788442551,"startTime":"0","endTime":"0","summary":"Tonix highlights TONMYA fibromyalgia launch, pipeline progress in investor presentationTonix investor presentation highlighted TONMYA’s commercial ramp, citing USD 11 million net sales in 2Q’26.Total ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL8hbhlH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4139","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874925","title":"Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874925","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874925?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:23","pubTimestamp":1788438210,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions  said Thursday that it has completed the repurchase of $75 million aggregate principal amount of 3.875% senior unsecured notes due 2028.The biopharmaceutical company deployed about $68 million in cash toward the effort, representing an average repurchase price of 90.6% of face value.The buyback reduces the aggregate principal amount of senior unsecured notes due 2028 to approximately $364.7 million, the company said, adding that it continues to evaluate market conditions for refinancing the remaining outstanding senior unsecured notes, which mature in Aug. 2028.Shares of the company were up 1.9% in Thursday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRGO","EBS","BK4139","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664713918","title":"Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2664713918","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664713918?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:45","pubTimestamp":1788435900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUAC5HLTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4583","EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664844855","title":"Inovio Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844855","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844855?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:24","pubTimestamp":1788384240,"startTime":"0","endTime":"0","summary":"DJ Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Inovio Pharmaceuticals Inc.  rallied 2.26% to $1.36 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 0.45% to 26,217.83 and the Dow Jones Industrial Average  rising 0.56% to 53,061.95.This was the stock's second consecutive day of gains.Inovio Pharmaceuticals Inc. closed 54.35% below its 52-week high of $2.98, which the company reached on September 9th.The stock outperformed some of its competitors Wednesday, as Johnson & Johnson  rose 1.48% to $275.21, Statera Biopharma Inc.  remained unchanged, and Pfizer Inc.  rose 1.65% to $29.02.Trading volume  eclipsed its 50-day average volume of 3.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 2, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4568","INO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841456","title":"Quest Diagnostics Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841456","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841456?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382800,"startTime":"0","endTime":"0","summary":"DJ Quest Diagnostics Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Quest Diagnostics Inc.  rallied 1.94% to $240.80 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.46% to 7,666.60 and the Dow Jones Industrial Average  rising 0.56% to 53,061.95.The stock's rise snapped a four-day losing streak.Quest Diagnostics Inc. closed 2.59% below its 52-week high of $247.19, which the company reached on August 27th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as UnitedHealth Group Inc.  rose 0.85% to $399.66, IQVIA Holdings Inc.  rose 2.13% to $263.84, and Centene Corp.  rose 3.23% to $67.34.Trading volume  eclipsed its 50-day average volume of 957,490.Data source: Dow Jones Market Data, FactSet. Data compiled September 2, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823417653.USD","LU0950375773.USD","LU0823417737.USD","LU1854103824.USD","LU2506952097.USD","LU1854104046.USD","BK4583","BK4196","LU2506951875.HKD","LU2506951958.HKD","LU2506952170.USD","BK4567","BK4585","BK4588","DGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664499688","title":"Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664499688","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664499688?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:13","pubTimestamp":1788380002,"startTime":"0","endTime":"0","summary":"Gilead CEO Daniel O'Day disposes of USD 2.23 million in common sharesGilead Sciences Chairman and CEO Daniel Patrick O’Day sold 14,000 common shares on Sep. 1, 2026.Sales priced at about $147.51 to $1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL5HTC5L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","LU1066053197.SGD","LU1066051498.USD","LU0965509101.SGD","LU2324357040.USD","LU0114720955.EUR","IBB","LU0289739699.SGD","TBXU","IBBQ","BBH","IE00BSNM7G36.USD","LU1839511570.USD","BK4578","LU0889565916.HKD","LU1674673691.USD","LU0823416689.USD","LU1571399168.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","LU1057294990.SGD","LU1061106388.HKD","MEDI","IE00BZ1G4Q59.USD","BMED","GILD","LU1934455194.USD","IE0002270589.USD","LU1934455277.USD","TMED","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU2087621335.USD","BIB","LU0965509283.SGD","LU0122379950.USD","BK4568","LU0861579265.USD","LU0965509010.AUD","LU1023059063.AUD","BK4585","LU1585245621.USD","SG9999015978.USD","LU0965508806.USD","IE00B19Z3B42.SGD","LU0859254822.USD","LU2357627491.SGD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664869440","title":"Emergent BioSolutions Secures New BARDA Anthrax Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2664869440","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664869440?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:36","pubTimestamp":1788294979,"startTime":"0","endTime":"0","summary":"Emergent Biosolutions ( ($EBS) ) has issued an announcement. Emergent BioSolutions, a biopharmaceutical company specializing in biodefense and medi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/emergent-biosolutions-secures-new-barda-anthrax-contract?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/emergent-biosolutions-secures-new-barda-anthrax-contract?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","BK4139","EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664999869","title":"Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664999869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664999869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:35","pubTimestamp":1788294900,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  rallied 2.45% to $149.92 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.71% to 7,631.47 and Dow Jones Industrial Average  falling 0.79% to 52,766.88.This was the stock's second consecutive day of gains.Gilead Sciences Inc. closed 4.69% short of its 52-week high of $157.29, which the company reached on February 11th.The stock outperformed some of its competitors Tuesday, as Johnson & Johnson  rose 2.01% to $271.19, Pfizer Inc.  rose 0.32% to $28.55, and Abbott Laboratories  fell 1.30% to $108.93.Trading volume  remained 2.1 million below its 50-day average volume of 6.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 1, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0965509283.SGD","LU1674673428.USD","BK4583","LU1571399168.USD","TBXU","BBH","LU0965509101.SGD","LU2324357040.USD","BK4568","IE0002270589.USD","SG9999015952.SGD","SG9999015986.USD","LU0889565916.HKD","LU2468319806.SGD","BK4532","IBB","LU1066051498.USD","BK4585","LU0859254822.USD","BK4578","IE00BSNM7G36.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU1934455194.USD","LU1934455863.HKD","LU2087621335.USD","LU0882574055.USD","MEDI","BMED","GILD","LU1061106388.HKD","SG9999015945.SGD","LU0234570918.USD","LU0965509010.AUD","LU0965508806.USD","LU2357627491.SGD","LU1839511570.USD","LU1934455277.USD","IE00BZ1G4Q59.USD","LU1037948541.HKD","LU1066053197.SGD","IE00B19Z3B42.SGD","LU2112291526.USD","LU0109394709.USD","LU1037948897.HKD","LU1430594728.SGD","BK4139","IE00B19Z3581.USD","LU0823416689.USD","LU1023059063.AUD","IBBQ","LU1585245621.USD","BK4588","LU0114720955.EUR","LU2089984988.USD","TMED","IE00B3T34201.USD","LU1674673691.USD","LU0861579265.USD","LU1778281490.HKD","LU0320765992.SGD","SG9999015978.USD","BK4550","BIB","BK4566","LU0122379950.USD","LU0058720904.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664901869","title":"Moderna Inc. Stock Advances 9.9%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2664901869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664901869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:33","pubTimestamp":1788294780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. rallied 9.9% to $154.27 on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 1.0% to 26,099.77 and Dow Jones Industrial Average falling 0.8% to 52,766.88.This was the stock's second consecutive day of gains.Moderna Inc. closed 12.7% short of its 52-week high of $176.66, which the company achieved on August 19th.The stock outperformed some of its peers, as Johnson & Johnson rose 2.0% to $271.19, Pfizer Inc. rose 0.3% to $28.55, and Gilead Sciences Inc. rose 2.45% to $149.92.Trading volume totaled 25.3 million, compared to the 50-day average of 16.8 million.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","TBXU","IBBQ","LU0109394709.USD","LU1037948541.HKD","BIB","BK4139","SG9999015945.SGD","LU0289739699.SGD","BK4583","LU1571399168.USD","IE00B7SZLL34.SGD","BK4501","BK4568","LU1934455194.USD","BK4551","LU0965509010.AUD","MRNA","BMED","BK4534","LU2324357040.USD","MRNY","BK4566","LU2468319806.SGD","LU1934455277.USD","BK4533","IE00BZ1G4Q59.USD","LU1057294990.SGD","LU0058720904.USD","IBB","LU0234570918.USD","IE00B19Z3B42.SGD","GNOM","BBH","LU0861579265.USD","LU1934455863.HKD","WDNA","LU0823416689.USD","LGHT","LU1430594728.SGD","LU0965508806.USD","IDNA","TMED","LU1066053197.SGD","MRNX","GILD","BK4588","MEDI","LU0320765992.SGD","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664776866","title":"Emergent BioSolutions: Got Contract Modification of Barda Av7909 Contract from Office of Assistant Secretary for Preparedness and Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2664776866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664776866?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:14","pubTimestamp":1788293672,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0TR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4139","EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664667738","title":"Emergent BioSolutions - Contract Modification for Procurement of Additional Cyfendus (Av7909) Doses - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664667738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664667738?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:14","pubTimestamp":1788293672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0TR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4583","EBS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":68,"code":"91000000","status":"200"}]}}